Cargando…
Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial
BACKGROUND: Antiviral therapies against the novel coronavirus SARS-CoV-2, which has caused a global pandemic of respiratory illness called COVID-19, are still lacking. METHODS: Our study (ClinicalTrials.gov: NCT04252885, named ELACOI), was an exploratory randomized (2:2:1) controlled trial assessing...
Autores principales: | Li, Yueping, Xie, Zhiwei, Lin, Weiyin, Cai, Weiping, Wen, Chunyan, Guan, Yujuan, Mo, Xiaoneng, Wang, Jian, Wang, Yaping, Peng, Ping, Chen, Xudan, Hong, Wenxin, Xiao, Guangming, Liu, Jinxin, Zhang, Lieguang, Hu, Fengyu, Li, Feng, Zhang, Fuchun, Deng, Xilong, Li, Linghua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7235585/ https://www.ncbi.nlm.nih.gov/pubmed/32838353 http://dx.doi.org/10.1016/j.medj.2020.04.001 |
Ejemplares similares
-
Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19
por: Zhu, Zhen, et al.
Publicado: (2020) -
Pharmacokinetic interactions between the potential COVID-19 treatment drugs lopinavir/ritonavir and arbidol in rats
por: HU, Yunzhen, et al.
Publicado: (2021) -
Factors associated with clinical outcomes in patients with Coronavirus Disease 2019 in Guangzhou, China
por: Lei, Chunliang, et al.
Publicado: (2020) -
Lopinavir/ritonavir monotherapy in clinical practice
por: Caso, A, et al.
Publicado: (2010) -
Lopinavir-Ritonavir-Kombination nicht wirksam
por: Diener, Hans-Christoph
Publicado: (2020)